Compare · NEOG vs QCLS
NEOG vs QCLS
Side-by-side comparison of Neogen Corporation (NEOG) and Q/C Technologies Inc. (QCLS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NEOG and QCLS operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $2.38B, about 877.7x QCLS ($2.7M).
- NEOG has been more active in the news (13 items in the past 4 weeks vs 3 for QCLS).
- NEOG has more recent analyst coverage (6 ratings vs 0 for QCLS).
- Company
- Neogen Corporation
- Q/C Technologies Inc.
- Price
- -
- -
- Market cap
- $2.38B
- $2.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1989
- 2014
- News (4w)
- 13
- 3
- Recent ratings
- 6
- 0
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest NEOG
- Chief Scientific Officer Yarwood Jeremy exercised 16,207 shares at a strike of $11.82, covered exercise/tax liability with 7,156 shares and sold $114,676 worth of shares (9,051 units at $12.67) (SEC Form 4)
- Neogen Corporation filed SEC Form 8-K: Other Events
- Chief Commercial Officer Freels Joe B was granted 6,345 shares (SEC Form 4)
- Neogen® To Participate in 2026 UBS Global Healthcare Conference
- VP, Animal Health Hastings Gregory S exercised 1,211 shares at a strike of $12.21 and covered exercise/tax liability with 337 shares, increasing direct ownership by 3% to 33,449 units (SEC Form 4)
- Director Woteki Catherine E exercised 1,776 shares at a strike of $12.21, increasing direct ownership by 6% to 29,507 units (SEC Form 4)
- Director Rodriguez Rafael A exercised 1,776 shares at a strike of $12.21, increasing direct ownership by 6% to 31,211 units (SEC Form 4)
- SEC Form 3 filed by Neogen Corporation
- Director Gupta Aashima exercised 1,776 shares at a strike of $12.21, increasing direct ownership by 5% to 38,180 units (SEC Form 4)
- Director Green Ronald D exercised 1,776 shares at a strike of $12.21, increasing direct ownership by 7% to 29,044 units (SEC Form 4)
Latest QCLS
- Q/C Technologies Reports Over $10 Million in Cash and Investments to Fund Development of Its Optical Processing Unit
- SEC Form 10-Q filed by Q/C Technologies Inc.
- Q/C Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Executive Chairman Silverman Joshua was granted 94,010 shares, increasing direct ownership by 80% to 210,845 units (SEC Form 4)
- Amendment: Executive Chairman Silverman Joshua was granted 16,806 shares, increasing direct ownership by 17% to 116,835 units (SEC Form 4)
- Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab
- SEC Form 3 filed by new insider Ehrlichman Yossef
- Q/C Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Q/C Technologies Names Yossef Ehrlichman Chief Technology Officer to Lead Optical Processor Development
- Q/C Technologies Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits